Ticker >

Windlas Biotech share price

Windlas Biotech Ltd.

NSE: WINDLAS BSE: 543329 SECTOR: Pharmaceuticals & Drugs  82k   87   28

528.75
-4.95 (-0.93%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 537.1

Today's Low

₹ 505

52 Week High

₹ 590

52 Week Low

₹ 244.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1099.72 Cr.

Enterprise Value

1074.72 Cr.

No. of Shares

2.08 Cr.

P/E

20.89

P/B

2.55

Face Value

₹ 5

Div. Yield

0.76 %

Book Value (TTM)

₹  207.54

CASH

25.45 Cr.

DEBT

0.44 Cr.

Promoter Holding

62.82 %

EPS (TTM)

₹  25.31

Sales Growth

10.12%

ROE

10.75 %

ROCE

14.38%

Profit Growth

10.59 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.12%
3 Year15.98%
5 Year9.88%

Profit Growth

1 Year10.59%
3 Year21.66%
5 Year20.33%

ROE%

1 Year10.75%
3 Year8.72%
5 Year10.03%

ROCE %

1 Year14.38%
3 Year11.54%
5 Year13.44%

Debt/Equity

0.0011

Price to Cash Flow

18.03

Interest Cover Ratio

73.5916030534351

CFO/PAT (5 Yr. Avg.)

0.970130772775692

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 62.82 0
Dec 2023 62.82 0
Sep 2023 62.82 0
Jun 2023 62.82 0
Mar 2023 62.38 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.6647754912503% for the Past 3 years.
  • The company has shown a good revenue growth of 15.9831951479596% for the Past 3 years.
  • The company has significantly decreased its debt by 5.677 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 73.5916030534351.
  • The company has an efficient Cash Conversion Cycle of 36.6777557375679 days.
  • Company has a healthy liquidity position with current ratio of 2.9246531713007.
  • The company has a high promoter holding of 62.82%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 10.4433245871658.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 119.7 140.71 144.79 152.67 162.21
Total Expenditure 105.76 124.27 127.64 133.99 141.88
Operating Profit 13.95 16.44 17.14 18.69 20.34
Other Income 2.16 2.33 2.62 3.24 3.16
Interest 0.16 0.16 0.24 0.29 0.31
Depreciation 3.14 3.57 3.19 3.33 3.39
Exceptional Items 0 0 0 0 0
Profit Before Tax 12.82 15.05 16.34 18.31 19.81
Tax 3.63 3.6 4.28 4.28 4.71
Profit After Tax 9.19 11.45 12.07 14.03 15.1
Adjusted EPS (Rs) 4.29 5.47 5.8 6.75 7.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 288.2 328.85 427.6 465.93 513.08
Total Expenditure 243.74 287.39 372.91 413.04 452.84
Operating Profit 44.47 41.47 54.69 52.9 60.24
Other Income 2.12 2.49 3.09 6.71 9.97
Interest 3.64 2.53 1.29 1.42 0.79
Depreciation 8.09 9.29 12.97 12.15 12.36
Exceptional Items 0 0 -32.35 0 0
Profit Before Tax 34.86 32.13 11.18 46.04 57.06
Tax 12.39 8.46 6.17 7.48 14.41
Net Profit 22.47 23.68 5.01 38.56 42.64
Adjusted EPS (Rs.) 12.34 13.01 2.75 17.69 20.38

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 6.41 6.41 6.41 10.9 10.46
Total Reserves 187.61 213.94 192.58 384.23 392.2
Borrowings 5.82 1.21 0.83 0.44 0.11
Other N/C liabilities -0.78 1.66 2.75 -0.23 3.33
Current liabilities 96.12 125.29 93.42 93.65 120.88
Total Liabilities 295.17 348.52 295.99 488.99 526.98
Assets
Net Block 61.93 70.26 95.94 91.18 109.41
Capital WIP 4.58 0 0.04 7.58 13.8
Intangible WIP 0 0 0 0.43 0.98
Investments 104.69 104.69 0.03 0.03 0.03
Loans & Advances 7.42 5.4 5.84 5.39 43.31
Other N/C Assets 0.18 0.13 0 2.73 5.92
Current Assets 116.38 168.03 194.15 381.63 353.54
Total Assets 295.17 348.52 295.99 488.99 526.98
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 34.86 32.13 11.18 46.04 57.06
Adjustment 9.87 9.77 46.85 9.75 7.35
Changes in Assets & Liabilities -9.28 -3.53 -40.05 -37.91 6.29
Tax Paid -13.37 -13.46 -6.53 -8.88 -9.72
Operating Cash Flow 22.08 24.91 11.45 9 60.98
Investing Cash Flow -6.59 -14.25 -14.53 -154.31 -14.11
Financing Cash Flow -8.17 -5.44 0.78 130.09 -43.74
Net Cash Flow 7.32 5.22 -2.3 -15.22 3.13

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 62.38 62.82 62.82 62.82 62.82
akw wbl family private tr... 40.01 40.30 40.30 40.30 40.30
ashok kumar windlass 21.01 21.16 21.16 21.16 21.16
vimla windlass - - 1.37 1.37 1.37
vimla windlass 1.36 1.37 - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 37.62 37.18 37.18 37.18 37.18
icici prudential smallcap... 9.35 9.41 9.40 9.36 9.33
llp 0.07 - 0.27 0.35 0.12
perpetuity health to weal... - - - 1.01 1.11
uti - healthcare fund - 1.04 1.04 1.04 1.04
uti- healthcare fund 1.03 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Windlas Biotech commissions injectable facility to manufacture small volume parenteral products2 Apr 2024, 5:38PM Windlas Biotech informs about press release2 Apr 2024, 11:25AM Windlas Biotech informs about analyst meet20 Feb 2024, 5:28PM Windlas Biotech informs about analyst meet20 Feb 2024, 4:49PM Windlas Biotech informs about analyst meet14 Feb 2024, 3:37PM Windlas Biotech - Quaterly Results8 Feb 2024, 2:30PM Windlas Biotech - Quaterly Results8 Feb 2024, 2:30PM Windlas Biotech - Quaterly Results8 Feb 2024, 2:30PM Windlas Biotech - Quaterly Results8 Nov 2023, 2:31PM Windlas Biotech informs about board meeting 30 Oct 2023, 2:24PM Windlas Biotech informs about grant of stock options17 Oct 2023, 2:43PM Windlas Biotech informs about newspaper advertisements19 Aug 2023, 1:06PM Windlas Biotech informs about earnings call transcript16 Aug 2023, 4:34PM Windlas Biotech - Quaterly Results8 Aug 2023, 1:43PM Windlas Biotech - Quaterly Results8 Aug 2023, 1:43PM Windlas Biotech - Quaterly Results8 Aug 2023, 1:43PM Windlas Biotech - Quaterly Results5 May 2023, 7:18PM Windlas Biotech - Quaterly Results5 May 2023, 7:18PM Windlas Biotech informs about disclosure 4 May 2023, 4:57PM Windlas Biotech informs about disclosure4 Apr 2023, 12:49PM Windlas Biotech informs about disclosure 21 Mar 2023, 1:06PM Windlas Biotech informs about disclosure16 Mar 2023, 4:54PM Windlas Biotech informs about analyst meet22 Feb 2023, 12:17PM Windlas Biotech informs about conference call transcript14 Feb 2023, 5:28PM Windlas Biotech informs about appointment of CEO cum KMP9 Feb 2023, 3:26PM Windlas Biotech - Quaterly Results8 Feb 2023, 3:29PM Windlas Biotech - Quaterly Results8 Feb 2023, 3:29PM Windlas Biotech - Quaterly Results8 Feb 2023, 3:29PM Windlas Biotech informs about daily report10 Jan 2023, 4:54PM Windlas Biotech informs about analyst meet5 Dec 2022, 5:23PM Windlas Biotech informs about investors meeting 30 Nov 2022, 3:05PM Windlas Biotech - Quaterly Results8 Nov 2022, 3:01PM Windlas Biotech - Quaterly Results8 Nov 2022, 3:01PM Windlas Biotech - Quaterly Results8 Nov 2022, 3:01PM Windlas Biotech informs about conference call5 Nov 2022, 2:30PM Windlas Biotech informs about board meeting intimation31 Oct 2022, 4:25PM Windlas Biotech informs about certificate 11 Oct 2022, 4:45PM Windlas Biotech informs about analyst meet22 Sep 2022, 2:29PM Windlas Biotech informs about outcome of AGM19 Sep 2022, 4:58PM Windlas Biotech informs about investor meet8 Sep 2022, 2:23PM Windlas Biotech informs about newspaper advertisements27 Aug 2022, 2:59PM Windlas Biotech informs about 21st AGM27 Aug 2022, 12:35PM Windlas Biotech informs about book closure 25 Aug 2022, 4:54PM Windlas Biotech - Quaterly Results4 Aug 2022, 2:48PM Windlas Biotech - Quaterly Results4 Aug 2022, 2:48PM Windlas Biotech - Quaterly Results4 Aug 2022, 2:48PM Windlas Biotech informs about analyst meet20 Jun 2022, 4:57PM Windlas Biotech gets EU-GMP certificate for Plant-IV at Dehradun25 May 2022, 9:46AM Windlas Biotech - Quaterly Results12 May 2022, 4:12PM Windlas Biotech - Quaterly Results12 May 2022, 4:12PM

Windlas Biotech Stock Price Analysis and Quick Research Report. Is Windlas Biotech an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Windlas Biotech and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Windlas Biotech cash from the operating activity was Rs 60.982 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Windlas Biotech has a Debt to Equity ratio of 0.0011 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Windlas Biotech , the EPS growth was 15.1757152384505 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Windlas Biotech has OPM of 11.7411802768753 % which is a bad sign for profitability.
     
  • ROE: Windlas Biotech have a average ROE of 10.7529782880312 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Windlas Biotech is Rs 528.45. One can use valuation calculators of ticker to know if Windlas Biotech share price is undervalued or overvalued.
Last Updated on:
Brief about Windlas Biotech

Windlas Biotech Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Windlas Biotech Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and branded pharmaceutical products. Established in [year], the company has emerged as a prominent player in the Indian pharmaceutical industry, with a strong focus on quality and innovation.

Windlas Biotech Limited - Share Price

As a long-term stock investor, understanding the share price of Windlas Biotech Limited is crucial. Our pre-built screening tools offer real-time data and insights into the company's share price movement, enabling investors to make informed decisions. Whether you are tracking the stock's performance or analyzing historical trends, our tools provide a comprehensive analysis of the share price.

Windlas Biotech Limited - Balance Sheet

Windlas Biotech Limited's balance sheet is a comprehensive overview of the company's financial health. Using our premium features like the DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont Analysis, investors can calculate fair value and gain valuable insights into the company's financial position. We provide a downloadable version of the annual report, which includes detailed financial statements for a thorough analysis.

Windlas Biotech Limited - Annual Report

The annual report of Windlas Biotech Limited provides a comprehensive review of the company's performance, achievements, and future plans. It includes detailed financial statements, auditor's report, and management discussion and analysis. The annual report serves as a valuable resource for long-term stock investors, offering a deeper understanding of the company's operations and growth prospects.

Windlas Biotech Limited - Dividend

Dividends are an attractive aspect for long-term investors, providing a steady income stream. Windlas Biotech Limited's dividend history and policy can be explored through our platform. The company's commitment to rewarding shareholders is reflected in its dividend distribution. Investors can track historical dividend payments and make informed decisions accordingly.

Windlas Biotech Limited - Quarterly Results

Quarterly results play a crucial role in assessing a company's performance and its potential for growth. Our platform offers downloadable quarterly reports, enabling investors to analyze key financial metrics, such as revenue, earnings, and cash flow. With our tools, investors can delve deeper into the numbers and understand the underlying factors driving the company's quarterly results.

Windlas Biotech Limited - Stock Price

Tracking the stock price of Windlas Biotech Limited helps investors stay informed about market trends and make well-informed investment decisions. Our pre-built screening tools provide real-time data on the stock price, allowing investors to monitor the company's performance and identify potential buying or selling opportunities.

Windlas Biotech Limited - Price Chart

Price charts are powerful tools that visualize the historical price movement of a stock. Our platform provides interactive price charts for Windlas Biotech Limited, allowing investors to analyze trends, patterns, and support/resistance levels. By understanding the price chart, investors can enhance their technical analysis and gain insights into future stock price movements.

Windlas Biotech Limited - News

Staying informed about the latest news and developments regarding Windlas Biotech Limited is crucial for long-term stock investors. Our platform curates news articles related to the company, providing investors with a comprehensive view of market trends, regulatory updates, and corporate announcements. Timely access to accurate news can help investors stay ahead and make informed decisions.

Windlas Biotech Limited - Concall Transcripts

For investors seeking more in-depth information about the company's performance, concall transcripts are a valuable resource. Our platform offers downloadable concall transcripts of Windlas Biotech Limited, providing insights into management's views, strategies, and future plans. These transcripts enable investors to gain a deeper understanding of the company's operations, achievements, and challenges.

Windlas Biotech Limited - Investor Presentations

Investor presentations provide a summarized overview of a company's performance, growth, and future prospects. Windlas Biotech Limited's investor presentations can be accessed and downloaded from our platform, offering valuable insights into the company's business model, market position, and expansion plans. These presentations serve as a reliable source for long-term investors looking for an overview of the company's investment potential.

Windlas Biotech Limited - Promoters

The promoters of Windlas Biotech Limited play a significant role in shaping the company's growth strategy and vision. Understanding the background, experience, and shareholding of the promoters can give investors an insight into the company's direction. Our platform provides detailed information about the promoters of Windlas Biotech Limited, empowering investors with valuable knowledge to make informed investment decisions.

Windlas Biotech Limited - Shareholders

Analyzing the shareholding pattern of Windlas Biotech Limited can provide insights into the company's ownership structure and investor confidence. Our platform offers a detailed breakdown of the shareholders, including institutional investors, promoters, and retail investors. Understanding the composition of the shareholder base is crucial for long-term investors seeking to assess the company's stability and growth potential.

With our comprehensive range of tools, reports, and analysis, long-term stock investors can gain valuable insights into Windlas Biotech Limited. From monitoring the share price and analyzing the balance sheet to accessing annual reports and concall transcripts, our platform equips investors with the necessary information to make well-informed investment decisions. Explore our pre-built screening tools, premium features, and downloadable reports to make the most of your investing journey.

Read More
X